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Abstract
In the previous issue of Arthritis Research & Therapy data are
presented showing that circulating immune complexes containing
citrullinated fibrin(ogen) are present in anti-citrullinated protein
antibody-positive rheumatoid arthritis patients, and that such
immune complexes co-localize with complement factor C3 in the
rheumatoid synovium. These results corroborate the idea that
citrullination is intimately involved in the pathophysiology of
rheumatoid arthritis and complete our model (the rheumatoid arthritis
cycle) for the development and chronic nature of this disease.
Rheumatoid arthritis (RA) is a chronic, progressive, inflam-
matory autoimmune disease characterized by the presence of
several autoantibodies. Among the autoantibodies detected
in RA, only rheumatoid factor and anti-citrullinated protein/
peptide antibodies (ACPAs) are considered clinically useful.
Both the measurement of antibodies directed against cyclic
citrullinated peptides (CCP) and rheumatoid factor determi-
nations are commonly used in daily clinical practice. Because
of the extreme specificity of ACPAs, we and others have
previously proposed that these antibodies might be involved
in the pathophysiology of RA. Since then, experimental
evidence supporting several pieces of the RA cycle (Figure 1)
has been obtained. In the previous issue of Arthritis Research
& Therapy, Zhao and colleagues [1] fill in one of the last gaps
in our knowledge on the cycle of events leading to RA. The
authors utilized complement C1q to capture immune
complexes (ICs) from plasma and protein G to capture ICs
from pannus tissue derived from human RA and control
patients, and demonstrated that ICs containing citrullinated
fibrin(ogen) were present in about 50% of anti-CCP-positive
patients. They were not detectable in RA patients lacking
these antibodies and control patients with other autoimmune
diseases. In the rheumatoid synovium, fibrin(ogen)-containing
ICs co-localize with complement factor C3, suggesting that
they contribute to synovitis in a subset of patients.
There are many citrullinated proteins in the inflamed RA
synovium [2] - for example, vimentin, histones, collagen types
I and II, and α-enolase - but citrullinated fibrin(ogen) is
certainly one of the most abundant and important antigens
[3]. The fact that only half of the anti-CCP(+) patients
possess ICs with citrullinated fibrin(ogen), however,
illustrates the heterogeneity in the ACPA repertoire. It is likely
that ICs in the other anti-CCP(+) patients contain one or
more of the other citrullinated antigens. The important study
of Zhao and collaborators cements into place one of the last
pieces of the RA cycle, as depicted in Figure 1 and
discussed by us and others previously [4-6]. In this model for
the development and chronicity of RA at least five steps can
be distinguished.
Step 1
An in itself innocent inflammation of the joint or other tissue in
the body leads to infiltration of inflammatory cells (granulo-
cytes, monocytes, lymphocytes). In normal situations many of
the infiltrating cells will die via apoptosis and will be cleared
(removed) by phagocytes. However, when there is massive
apoptosis, for example due to a toxicant or infection, or a
(genetic) defect in the clearance system, some apoptotic
cells may become necrotic. Granulocytes and monocytes,
and macrophages emerging from monocyte differentiation,
contain citrullinating peptidylarginine deiminase (PAD)
enzymes. These enzymes are activated by the elevation of
cytosolic Ca2+-concentrations, for example when cells under-
go apoptosis.
Step 2
When the dying inflammatory cells are not cleared properly
and become necrotic, they release the intracellular citrullinated
proteins (for example, histones, vimentin) and the activated
PAD enzymes. These enzymes, PAD2 and/or PAD4, can then
citrullinate extracellular synovial proteins like fibrin(ogen).
Editorial
An important step towards completing the rheumatoid arthritis cycle
Walther J van Venrooij and Ger JM Pruijn
Department of Biomolecular Chemistry, Radboud University Nijmegen, NL-6500 HB Nijmegen, The Netherlands
Corresponding author: Walther J van Venrooij, w.vanvenrooij@ncmls.ru.nl
Published: 19 September 2008 Arthritis Research & Therapy 2008, 10:117 (doi:10.1186/ar2504)
This article is online at http://arthritis-research.com/content/10/5/117
© 2008 BioMed Central Ltd
See related research article by Zhao et al., http://arthritis-research.com/content/10/4/R94
ACPA = anti-citrullinated protein/peptide antibody; CCP = cyclic citrullinated peptide; IC = immune complex; PAD = peptidylarginine deiminase;
RA = rheumatoid arthritis.Page 2 of 3
(page number not for citation purposes)
Arthritis Research & Therapy    Vol 10 No 5 van Venrooij and Pruijn
However, the mere presence of citrullinated proteins will not
necessarily lead to chronic inflammation because in 99% of
individuals these citrullinated proteins are degraded without a
(humoral) reaction of the immune system [4]. The presence of
a large number of citrullinated proteins in the inflamed
synovium has been shown by several groups (for a recent
review, see [2]).
Step 3
In those individuals who are able to present citrullinated
fragments of proteins to T cells via certain HLA molecules, an
immune response to citrullinated antigens might be genera-
ted, resulting in the production of high affinity IgG ACPAs [7].
Activation of autoreactive B cells may occur locally in the
(inflamed) joint, but may also occur in other inflamed tissues.
Via the circulation, these ACPAs or the plasma cells
producing them will ultimately enter the joint, for example
when a local inflammation occurs or as a result of immune
complex-facilitated vascular leakage [6]. Irrespective of the
site of B cell activation, there is experimental evidence that
ACPAs are produced in RA joints and may mediate tissue
injury [2,8].
Recent support for a mechanism as described above has
been provided by Hill and collaborators [9]. They showed that
citrullinated fibrinogen is able to induce arthritis in DR4-IE
transgenic mice. T cell epitope scanning and antibody
microarray analysis identified a unique pattern of citrulline-
specific reactivity that was not found in DR4-IE transgenic
mice immunized with unmodified fibrinogen or in wild-type
C57BL/6 mice immunized with citrullinated fibrinogen. These
observations directly implicate citrullinated fibrinogen as
arthritogenic in the context of RA-associated major histo-
compatibility (MHC) class II molecules [9]. It is quite likely
that this also holds for other citrullinated antigens, such as
vimentin and histones.
Step 4
After their production in/entry into the inflamed synovium,
ACPAs can react with the abundantly available citrullinated
antigens. The paper of Zhao and collaborators [1] is the first
to show the presence of such ICs in circulating plasma as
well as in the inflamed synovium. These ICs stimulate the
inflammatory process by activation of the complement system
and further recruitment and activation of granulocytes,
monocytes, and macrophages via both complement receptor-
and Fcγ receptor-dependent pathways. In this way, ACPAs
contribute to the perpetuation of joint inflammation and to the
chronicity and severity of RA.
Step 5
New monocytes and granulocytes will enter the synovium,
where they will be activated, subsequently die and release
another load of activated PAD enzymes. A new round of
Figure 1
The rheumatoid arthritis (RA) cycle. Model for the role of protein citrullination in the pathophysiology of RA. The various aspects of the five major steps
are depicted. Step 1, entry and death of inflammatory cells in the synovium; step 2, peptidylarginine deiminase (PAD) activation and protein
citrullination; step 3, immune response to citrullinated antigens; step 4, formation of citrullinated immune complexes and their effects; step 5,
recruitment of new inflammatory cells. ACPA, anti-citrullinated protein/peptide antibody.Page 3 of 3
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citrullinated antigens and ACPA production will take place,
leading to a new flare of inflammation. It has been noted that
novel IgM-producing B cells are continuously recruited to the
inflamed RA joint, demonstrating that the ACPA response is
continuously reactivated during the course of arthritis [10].
The continuation of this vicious circle for years, eventually
accompanied by fresh traumas or environmental events that
stimulate inflammation, will ultimately lead to a chronic
inflammation that manifests as the disease we know as RA.
The paper of Zhao and collaborators proves one of the last
suppositions of the RA cycle. This model will allow us to
design new strategies to interfere with the chronic cycle of
events in the inflamed joints, which may ultimately lead to the
development of new and more specific therapies for RA.
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